Breaking AI & Tech News Analyzed

Manchester United’s chief executive Omar Berrada told the Inside Carrington podcast that the club would "like him to stay" regarding captain Bruno Fernandes, yet stopped short of guaranteeing his future beyond the 2026‑27 season.Berrada Signals Uncertainty Over Bruno Fernandes’ FutureFernandes, the Football Writers’ Footballer of the Year with a record‑breaking 21 Premier League assists, has sent mixed signals. In November he said he felt "hurt" by the club and considered leaving, but in March he reaffirmed his ambition to win the Premier League. Berrada emphasized Fernandes’ leadership off the pitch and his alignment with United’s values, while acknowledging the contract expires next summer with an optional 12‑month extension.Financial Context: Redundancies, £35m Ederson Deal and Contract TimelineRedundancy programme earlier this year cut roughly 450 staff positions, a cost Berrada admitted was "very high" but now shows "fruit" in recent financial results.United have agreed a £35 million fee with Atalanta for Brazilian midfielder Éderson, signalling continued investment despite tighter budgets.Fernandes’ current deal runs out in summer 2026, with a club‑option for an additional year.Potential Ripple Effects on United’s Transfer Strategy and Squad BalanceBerrada outlined a “clear plan” that avoids market or agent pressure, aiming to replicate last summer’s template of blending experience and youth. The uncertainty around Fernandes could influence:Whether United pursue a high‑profile replacement or promote internal talent.Budget allocation, given the £35 m outlay for Éderson and the need to respect the club’s financial discipline.Team dynamics, as Fernandes is praised for mentoring younger signings.What Next? Scenarios for Fernandes and United’s Summer PlansAnalysts see three likely outcomes:Renewal: United meet Fernandes’ terms, retaining the captain and building around his play‑making.Departure: Fernandes leaves on a free or for a modest fee, prompting United to accelerate the recruitment of midfield reinforcements.Staggered Exit: A short‑term extension is agreed, allowing United to plan a phased transition while maintaining squad stability.Regardless of the path, United’s emphasis on fiscal prudence and a balanced squad suggests any decision will be weighed against long‑term competitiveness in the Premier League.

The Final Bow for Football's GreatestThe FIFA World Cup 2026 could be the final act for some of football's finest talents. Although some of this tournament's players will set a men's football record by appearing in their sixth World Cup, age is catching up, and other players have struggled with injuries.Cristiano Ronaldo - Portugal's Ageless WonderAlthough fitness has been one of Ronaldo's biggest strengths during his illustrious career, at 41, the Portugal forward knows his playing days are numbered. Numbers have always been on the former Manchester United and Real Madrid forward's side, though, and he fired in 30 in 37 matches for Al-Nassr this season, while his tally for Portugal currently sits at 143 goals.The second-oldest player at this year's tournament, only behind Scotland's 43-year-old Craig Gordon, Ronaldo heads to his record sixth World Cup, well aware it could be his final chance to lift the coveted golden trophy: the only one missing from his glittering cabinet.Lionel Messi - Argentina's Final ChapterLike Ronaldo, Messi is also off to his record sixth finals appearance, one where he will lead Argentina's defense of the title they won in Qatar four years ago. Argentina's all-time leading scorer and appearance holder, Messi, has struggled with injury in the build-up to the tournament, raising doubts about whether he will feature in each game and if his body can keep up with the gruelling demands of an expanded World Cup.The eight-time Ballon d'Or winner's impact and talent, however, are such that, even at 38, he remains the heartbeat of the football-crazy South American nation.Luka Modric - Croatia's Midfield MaestroAfter playing a key role in Croatia's run to the 2018 final and a third-place finish in 2022, Modric is ready for his fifth and final appearance at the World Cup. As the 40-year-old heads to the tournament after undergoing cheekbone surgery, the veteran knows the team still relies heavily on him for his playmaking prowess.The ageing midfielder, also the Balkan nation's captain, still enjoys a hero's status within a side that has often defied expectations on the global stage. Enjoy his magic in midfield before he bows out.Neymar Jr - Brazil's Comeback KingAt 34, Brazil's all-time leading scorer Neymar is much younger than Messi or Ronaldo, but unlike the two greats of the game, his place in the national team is not guaranteed. Neymar's comeback in the Brazil squad after a two-and-a-half-year hiatus electrified football fandom, and only time will tell whether it was a gamble or a tactical masterclass by coach Carlo Ancelotti.With a history of fitness issues, a series of injuries and mounting age (he would be 38 by the 2030 World Cup), what looks more certain is that this could be Neymar's fourth and final act at the tournament.Manuel Neuer - Germany's Goalkeeping LegendSuch is the "aura" of Neuer, as coach Julian Nagelsmann said last month, that the 40-year-old came out of retirement to be named Germany's first-choice goalkeeper for the 2026 World Cup. Back in the squad after nearly two years, fans will have a final chance to see him at the World Cup.Widely regarded as one of the greatest goalkeepers, Neuer has played at four World Cups, most notably having a key role in Germany's 2014 World Cup triumph on Brazilian soil.Mohamed Salah - Egypt's African StarArguably Africa's greatest player of all time, Salah became a global superstar on the back of his success at Liverpool, where he won nine trophies. At 33, and no longer at the peak of his powers, this could be the forward's second, and possibly final, World Cup.An underwhelming season and his subsequent departure from Liverpool may have tempered expectations. Yet Egyptians continue to place their faith in their beloved number 10, hoping he can inspire the nation and help deliver something it has never experienced before: the joy of celebrating a World Cup victory.Kevin de Bruyne - Belgium's Playmaking EngineA big part of Belgium's "golden generation" between 2014 and 2022, playmaker De Bruyne continues to flourish in his duties for club and country. Age, however, is starting to catch up with the playmaker, who turns 35 later this month.The Napoli midfielder's performance is central to Belgium's odds of a deep run at the 2026 World Cup, and he will be eager to drive them to a memorable finish in what will be his fourth and presumably final appearance at the tournament.Virgil van Dijk - Netherlands' Defensive LeaderExperienced centre-back van Dijk is not quite the force he was a few years ago, when he won the Champions League and Premier League in back-to-back seasons with Liverpool. The Netherlands captain turns 35 next month, and the Dutch could move on with a younger defensive core by the time the 2030 edition comes around.After reaching the 2022 World Cup quarterfinals and Euro 2024 semifinals, van Dijk will hope to take the team one step further in what will be his third finals.Sadio Mane - Senegal's Inspirational CaptainWidely regarded as one of the world's best wingers, Mane heads to the World Cup seeking to make up for the disappointing leg injury that denied him a shot at Qatar 2022. At 34, the Senegal international is far from the peak of his career, which saw him enjoy trophy-laden spells at Liverpool and Bayern Munich.Despite his mounting age, Mane remains the team's source of inspiration and creativity, and he was an integral part of the side that beat Morocco in the Africa Cup of Nations final – only for the result to be overturned due to Senegal's mid-game protest.Mane will feature in his third, and likely final, World Cup, given that the Teranga Lion has said the last AFCON was his last, although the coaching team have said they have not given up on changing his mind.Guillermo Ochoa - Mexico's Record-Setting GoalkeeperPart of an esteemed group which includes Messi and Ronaldo, Ochoa is also set to play at a record sixth World Cup. The goalkeeper, who will turn 41 next month, had not been part of the national squad in recent years, but was picked for the tournament, which is being co-hosted by his country, Mexico.Known for being a formidable figure in Mexico's previous World Cup campaigns, Ochoa will retire at the end of the team's run at the tournament.The FIFA World Cup begins on June 11. You can follow the action on Al Jazeera's dedicated World Cup 2026 page with all the latest news, match build-up and live text commentary, and keep up to date with group standings, real-time match results and schedules.

Iran's football team is preparing for the 2026 FIFA World Cup while the nation remains embroiled in an active conflict with the United States and Israel, a scenario unprecedented in tournament history.Iran's World Cup Campaign Amid Ongoing US‑Israel ConflictThe war between Iran and the US‑Israel coalition began on 28 February 2026 and a tentative cease‑fire has been in place since 8 April 2026. Despite the uneasy pause, sporadic flare‑ups keep the end of hostilities uncertain, casting a shadow over Iran’s participation in a tournament hosted by the US, Canada and Mexico.Logistical Hurdles and Visa DelaysTeam preparations have been disrupted by a series of practical obstacles:More than two weeks of training in Antalya, Turkiye, with occasional trips to Ankara for US‑embassy visa applications.Visa approvals finally obtained from the Mexican embassy in Ankara, allowing travel to Mexico this weekend.Training base shifted from Tucson, Arizona, to Tijuana, Mexico, after US‑entry permit issues.First two group matches scheduled near Los Angeles, a city with a large Iranian diaspora.These logistical setbacks have forced the squad to adapt quickly while maintaining focus on on‑field performance.Psychological Impact on Players and Fan ExpectationsMidfielder Saeid Ezatolahi (29) acknowledged the mental strain: “It is not easy… the political situation can affect the mind of the players.” He added that the large Iranian community in Los Angeles will bring heightened pressure, but also motivation to “make them proud.”Young forward Mohammad Ghorbani (24) echoed the sentiment, emphasizing the team’s role in bringing joy to a nation “going through a lot of difficulties.” The dual burden of representing a war‑torn country and meeting diaspora expectations creates a unique psychological landscape for the squad.Future Outlook: Performance and Regional RepercussionsIran is placed in Group G with New Zealand, Belgium and Egypt. The team’s first match against New Zealand is set for 14 June 2026 at the Los Angeles Rams’ stadium in Inglewood, followed by Belgium on 21 June and Egypt on 26 June in Seattle.Success on the pitch could serve as a symbolic rallying point for Iranians at home and abroad, while continued conflict may amplify scrutiny on the nation’s diplomatic stance. Observers will watch whether the squad can translate resilience off the field into competitive results, potentially reshaping perceptions of Iranian sport amid geopolitical tension.

The LeadIn an unexpected turn of sports prediction, a shark has forecasted Brazil will begin the FIFA World Cup with a victory. This unusual oracle has captured global attention as football fans eagerly anticipate the tournament's kickoff.The Aquatic PredictionThe remarkable prediction emerged from a marine facility where researchers observed a shark consistently selecting Brazil's flag when presented with options of participating nations. The aquatic creature's choice has been interpreted as an omen for Brazil's successful tournament start.Sports Forecasting EvolutionThis unconventional method joins a long history of unusual World Cup predictions, from animals to inanimate objects. While scientific validity remains questionable, such predictions capture public imagination and add an element of fun to the serious business of football forecasting.Brazil's World Cup ProspectsBrazil, a five-time World Cup champion, enters the tournament as one of the favorites. The shark's prediction aligns with many analysts' views that Brazil possesses the talent and experience to make a strong start, though tournament success depends on numerous factors beyond initial results.

Google is requesting federal approval to deploy a massive sterile‑insect technique in the United States, aiming to curb mosquito‑borne diseases without relying on chemical pesticides.Google’s Debug Program Requests EPA Approval for Massive Mosquito ReleaseThe tech giant, through its Debug initiative, has filed a notice with the U.S. Environmental Protection Agency to release up to 16 million sterile male mosquitoes annually in Florida and California, totaling 32 million over a two‑year period. The request is open for public comment until 5 June 2026.Scale of the Proposed Release and Expected Suppression MetricsAnnual target: 16 million sterile males per state.Technology: Males are infected with the naturally occurring bacterium Wolbachia, which prevents viable offspring when they mate with wild females.Previous results: In Singapore, releases achieved 80‑90% suppression of Aedes aegypti populations and a 70%+ drop in dengue cases within 6‑12 months.Potential Public‑Health and Environmental Implications for the U.S.By focusing on the Aedes aegypti species—responsible for dengue, Zika, yellow fever and chikungunya—Google hopes to lower disease incidence without the ecological drawbacks of broad‑spectrum insecticides. The approach also aligns with growing calls for sustainable vector‑control methods, though critics warn about ecological unknowns and the need for rigorous monitoring.What Success Could Mean for Future Vector‑Control StrategiesIf EPA grants the permit and field trials confirm Singapore‑style outcomes, the model could be replicated across other high‑risk regions in the U.S., potentially reshaping public‑health policy toward data‑driven, biotech solutions. A positive result may also accelerate private‑sector investment in similar sterile‑insect programs, expanding the role of AI and automation in entomological research.

Emergency Funding Fuels Three Vaccine CandidatesThe Coalition for Epidemic Preparedness Innovations (CEPI) announced $60 million in emergency grants to fast‑track three vaccine programmes targeting the Bundibugyo strain of Ebola. The funding is split among IAVI, Oxford University (in partnership with the Serum Institute of India), and Moderna, each racing to move from pre‑clinical work to human trials.Projected Timelines for Vaccine TrialsIAVI vaccine: WHO labels it the “most promising candidate”. Expected to enter clinical trials in seven to nine months, though IAVI aims to accelerate.Oxford vaccine (ChAdOx1 Bundibugyo): Leveraging the same platform as the Oxford/AstraZeneca COVID‑19 jab, trials could start within two to three months pending animal data.Moderna vaccine: mRNA‑based candidate not yet on WHO’s list; pre‑clinical work could allow trial initiation within months after CEPI’s additional $50 million commitment.Financial Commitments and Their SignificanceThe combined $110 million from CEPI ($60 million emergency grant + $50 million for Moderna) underscores the urgency of a coordinated response. These funds cover pre‑clinical development, manufacturing scale‑up, and the logistical costs of conducting trials in a conflict‑affected region.Operational Challenges in the DRC and UgandaSecurity instability in eastern DRC—where militias have attacked Ebola treatment centres—has hampered trial set‑up and patient recruitment. Researchers, including Dr Richard Hatchett (CEPI CEO), stress that “every day counts” but note that safe trial execution depends on stabilising the environment and securing community trust.Potential Therapeutic Options Beyond VaccinesMonoclonal antibodies MBP134 and Maftivimab show promise in early studies.The antiviral remdesivir is being evaluated for efficacy against Bundibugyo.A novel prevention pill, obdeldesivir, demonstrated up to 100 % protection in monkey models when administered daily for ten days.Outlook: When Might Effective Countermeasures Arrive?If security conditions improve, the Oxford candidate could enter Phase 1 trials by late summer 2026, while IAVI’s schedule may see first‑in‑human dosing by early 2027. Moderna’s mRNA platform could follow a similar timeline, contingent on pre‑clinical results. Successful trials could lead to emergency use authorisations within a year of dosing, offering the first targeted tools against the Bundibugyo strain and informing preparedness for future Ebola outbreaks.

Lead: A rare Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda has triggered a rapid response, with three vaccine candidates entering emergency‑trial evaluation. While funding from the Coalition for Epidemic Preparedness Innovations (CEPI) accelerates research, the region’s insecurity and community mistrust pose significant hurdles to delivering a vaccine before the epidemic expands. Current Outbreak Metrics and Geographic Spread Confirmed cases in eastern DRC: 321 (as of 2 June 2026) Suspected cases in DRC: 116 Deaths in DRC: 48 Confirmed cases in Uganda: 15 (including 9 initially reported) Deaths in Uganda: 1 The outbreak began in Ituri province, an area already strained by armed conflict, and has reached Kampala, the Ugandan capital, highlighting the risk of cross‑border transmission. Funding and Vaccine Development Landscape IAVI receives $3.2 million to develop a vector‑based vaccine using a weakened animal virus. Moderna receives $50 million for an mRNA‑based candidate, leveraging the platform that proved effective against COVID‑19. University of Oxford receives $8.6 million for a chimpanzee‑adenovirus vector vaccine, similar to its COVID‑19 effort. All three candidates will be manufactured by the Serum Institute of India. CEPI has pledged to fast‑track emergency trials but has not disclosed specific timelines for Phase I/II studies. Historically, vaccine research for the Bundibugyo strain has lagged because the virus accounts for only a small fraction of global Ebola cases. Challenges to Vaccine Deployment in Conflict Zones Ongoing armed conflict in Ituri limits access for health workers and hampers cold‑chain logistics. Community mistrust, fueled by past incidents of treatment‑centre attacks, may lead to vaccine refusal or sabotage. Limited existing infrastructure for large‑scale immunisation in remote border regions. These factors echo previous outbreaks where vaccine roll‑out was delayed despite availability, underscoring the need for coordinated security and communication strategies. Projected Timeline and What Comes Next Initial safety and immunogenicity trials could begin within 12‑18 months, assuming regulatory clearance. Manufacturing scale‑up at the Serum Institute may add several months, potentially delivering doses by late 2027. Effective deployment will require simultaneous conflict‑mitigation efforts and community‑engagement campaigns to overcome stigma. Experts caution that without accelerated trial results and robust on‑the‑ground support, the outbreak could mirror the 2014 West‑Africa epidemic, which infected ~29 000 people and caused >11 000 deaths.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."